Abzena was recently featured in Pharmaceutical Technology magazine’s February eBook focused on affinity ligands.
A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.
Affinity ligands play an exciting role in the ever-growing sphere of downstream processing. In speaking with Pharmaceutical Technology®, Phillip Elliott, PhD, associate director of Process Development, BioCina; Jan Bekker, PhD, director, Business Development, Commercial and Technical Operations, BioCina; and Parviz Shamlou, PhD, senior vice-president of Science & Technology, Abzena illuminate the newest innovations with affinity ligands and provide a deeper understanding of the role affinity ligands play in the future of downstream processing.
Abzena’s Complex Biologic Expertise
With a comprehensive portfolio of antibody and protein engineering services, we offer integrated or stand-alone packages to achieve specific properties aligned with your desired target product profile for specificity, safety, stability, and functionality.
From discovery through to cell line development we can engineer, express, purify and characterize your molecules. Utilizing experience from successfully delivering many hundreds of projects, our experts work relentlessly to meet your needs, enhance efficiency, and mitigate risk.
